OncoSec Medical Incorporated kicked off the trading day on 10/10/19 with a price increase of 34.76%, equivalent to $0.57 relative change for the day. Taking a more long-term approach, ONCS had a 52-week range of $1.60 to $19.60. At the time of this article’s publishing, this stock is trading at $2.21 after starting the trading session at $2.19. At the time of writing, this stock’s 50-day Moving Average stands at $2.01, while the 200-day Moving Average of this stock is currently $4.15.
Currently, this company’s share volume is sitting at $11413656, but has maintained average daily volume of $86.79K. This stock has generated an average Year to Date volume of $167127, alongside an average 20-day volume of $642660. This publicly-traded company’s shares outstanding now amounts to $10.65 million, simultaneously with a float of $9.01 million. The organization now has a market capitalization sitting at $23.54 million.
OncoSec Medical Incorporated(ONCS) Ownership Data
Now let’s turn our focus to how large-scale investors are behaving with this stock. OncoSec Medical Incorporated’s current insider ownership accounts for 1.10%, in contrast to 20.00% institutional ownership. According to the most recent latest insider trade that took place on Jul 17 this organization’s Director bought 30,000 at the rate of 2.57, making the entire transaction hit 77,100 in total value, affecting insider ownership by 1,611,000. Preceding that transaction, on Jul 16 Company’s Director bought 60,000 at a price of 2.34, making the whole transaction’s value amount to 140,400. This particular insider is now the holder of 1,581,000 in total.
If we take a glance at the Ownership summary of OncoSec Medical Incorporated’s stock, Institutional holders make up 20.00% of its total stock ownership. All together, they are the legal holders of 10.65M shares. If we focus on the top 3 stockholders for this publicly-traded organization, Altium Capital Management LP owns 952,000 shares, with 683 Capital Management LLC in 2nd place owning 188,000 shares and The Vanguard Group, Inc. in third place with total ownership of 173,474 shares.
OncoSec Medical Incorporated (ONCS) Earnings and Revenue Data
In the latest quarterly report that this company released, which was put into the public domain on 4/29/2019, the organization reported -$1.03 earnings per share (EPS) for the three-month period, surpassing the consensus estimate (set at -$1.36) by $0.33.
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.78 per share during the current fiscal year.
OncoSec Medical Incorporated’s EPS increase for this current 12-month fiscal period is 8.20%, and is forecasted to reach -2.97 in the upcoming year.
Additional Trading Performance Indicators
Now turning our attention to the current performance indicators for OncoSec Medical Incorporated, this organization’s Quick Ratio in the last reported quarter now stands at 5.00. The company has managed to achieve an average true range (ATR) of 0.17. Alongside those, its Beta score is 2.28.
Plus, this company’s price to book ratio for the last three-month fiscal period reported is 0.69, whereas its price to cash per share for the last quarter landed at 2.19.
In the same vein, ONCS’s Diluted EPS (Earnings per Share) trailing twelve months was posted at -6.08, a figure that is expected to reach -0.92 in the next reported quarter, and analysts expect it will be -2.97 at the market close of one year from today’s date.